Sarah Sammons, MD

Sarah Sammons, MD, presents updated results from the ReDiscover trial at the 2025 ASCO Annual Meeting in Chicago, demonstrating that the mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant shows promising clinical activity and a manageable safety profile in patients with PIK3CA-mutant HR+/HER2– advanced breast cancer.

Sarah Sammons, MD, contextualizes the importance of T-DXd plus pertuzumab within the evolving ADC arsenal for HER2-positive breast cancer.

Sarah Sammons, MD, discusses early efficacy data with RLY-2608 plus fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer.

Sarah Sammons, MD, highlights ReDiscover trial findings, showcasing the durable efficacy, potent mutant-selective targeting, and favorable safety profile of RLY-2608 combined with fulvestrant in patients with PIK3CA-mutant HR+/HER2− advanced breast cancer, validating its potential as the first allosteric, pan-mutant PI3Kα inhibitor.

Sarah Sammons, MD, discusses the rationale for examining brain metastases in HER2-positive breast cancer, highlighting the implications of recent data.

Sarah Sammons, MD, discusses the real-world incidence of brain metastases in HER2-positive breast cancer per line of treatment as well as cumulatively.

Sarah Sammons, MD, discusses the goals of treating patients with breast cancer who present with active vs stable brain metastasis.

Sarah Sammons, MD, discusses whether CDK4/6 inhibitors should be considered a standard first line treatment within hormone receptor–positive, HER2-negative advanced breast cancer according to primary results from the phase 3 SONIA trial.

Sarah Sammons, MD, discusses findings from the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.